A top U.S. health insurer has dropped its coverage of Mylan NV’s brand-name EpiPen and switched to the half-priced version Mylan launched in response to public outrage over its sharp price increases on the lifesaving drug. Cigna Corp. swapped its coverage of the $600 EpiPen for Mylan’s $300 version, according to a document on Cigna’s website outlining its prescription drug coverage changes for 2017. Mylan’s launched the...

Source: Wall Street Journal January 12, 2017 17:19 UTC